Custom
Request 

Research Report Details

Author / Researcher : Global Markets Direct

Report Statistics

Number Of Pages/Tabs : 303

Number Of Charts : N/A

Published Date : 05/31/2016

Industries : Pharmaceuticals

Countries : All

Quality Score : 5

Have a question about this report?
24/7 Research Support
Talk to Zursh Analyst
+1 858 522 9998 or Email Us

Huntington Disease - Pipeline Review, H1 2016
Huntington Disease - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Huntington Disease - Pipeline Review, H1 2016’, provides an overview of the Huntington Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Huntington Disease - The report reviews pipeline therapeutics for Huntington Disease by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Huntington Disease therapeutics and enlists all their major and minor projects - The report assesses Huntington Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Huntington Disease Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Huntington Disease - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Huntington Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

;

Companies Covered

Addex Therapeutics Ltd AFFiRiS AG Angita B.V. Astellas Pharma Inc. Azevan Pharmaceuticals, Inc. BioCrea GmbH BioMarin Pharmaceutical Inc. BrainStorm Cell Therapeutics Inc. Diffusion Pharmaceuticals Inc. EncephRx, Inc. Evotec AG Galenea Corp. Genervon Biopharmaceuticals, LLC Immungenetics AG Ionis Pharmaceuticals, Inc. Ipsen S.A. Kadmon Corporation, LLC KineMed, Inc. Living Cell Technologies Limited Medesis Pharma S.A. Mitochon Pharmaceuticals, Inc. Neuralstem, Inc. Neurimmune Holding AG NeuroNascent, Inc. New World Laboratories, Inc. nLife Therapeutics, S.L. NsGene A/S Omeros Corporation Oryzon Genomics S.A. Otsuka Holdings Co., Ltd. Pfizer Inc. PharmatrophiX, Inc. ProQR Therapeutics N.V. QR Pharma, Inc. Raptor Pharmaceutical Corp. reMYND NV Rhenovia Pharma Limited Sangamo BioSciences, Inc. SOM Innovation Biotech SL Spark Therapeutics, Inc. Teva Pharmaceutical Industries Ltd. TyrNovo Ltd. Ultragenyx Pharmaceutical Inc. UniQure N.V. Vaccinex, Inc. Vertex Pharmaceuticals Incorporated VistaGen Therapeutics , Inc. VivaCell Biotechnology Espana S.L. Voyager Therapeutics, Inc. Vybion, Inc. WAVE Life Sciences Ltd. Wellstat Therapeutics Corporation
Table of Contents
Table of Contents 2
Introduction 6
Huntington Disease Overview 7
Therapeutics Development 8
Huntington Disease - Therapeutics under Development by Companies 10
Huntington Disease - Therapeutics under Investigation by Universities/Institutes 14
Huntington Disease - Pipeline Products Glance 16
Huntington Disease - Products under Development by Companies 19
Huntington Disease - Products under Investigation by Universities/Institutes 23
Huntington Disease - Companies Involved in Therapeutics Development 24
Huntington Disease - Therapeutics Assessment 76
Drug Profiles 87
Huntington Disease - Recent Pipeline Updates 219
Huntington Disease - Dormant Projects 277
Huntington Disease - Discontinued Products 284
Huntington Disease - Product Development Milestones 285
Appendix 291

List of Tables
Number of Products under Development for Huntington Disease, H1 2016 19
Number of Products under Development for Huntington Disease - Comparative Analysis, H1 2016 20
Number of Products under Development by Companies, H1 2016 21
Number of Products under Development by Companies, H1 2016 (Contd..1) 22
Number of Products under Development by Companies, H1 2016 (Contd..2) 23
Number of Products under Development by Companies, H1 2016 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2016 26
Comparative Analysis by Late Stage Development, H1 2016 27
Comparative Analysis by Clinical Stage Development, H1 2016 28
Comparative Analysis by Early Stage Development, H1 2016 29
Products under Development by Companies, H1 2016 30
Products under Development by Companies, H1 2016 (Contd..1) 31
Products under Development by Companies, H1 2016 (Contd..2) 32
Products under Development by Companies, H1 2016 (Contd..3) 33
Products under Investigation by Universities/Institutes, H1 2016 34
Huntington Disease - Pipeline by Addex Therapeutics Ltd, H1 2016 35
Huntington Disease - Pipeline by AFFiRiS AG, H1 2016 36
Huntington Disease - Pipeline by Angita B.V., H1 2016 37
Huntington Disease - Pipeline by Astellas Pharma Inc., H1 2016 38
Huntington Disease - Pipeline by Azevan Pharmaceuticals, Inc., H1 2016 39
Huntington Disease - Pipeline by BioCrea GmbH, H1 2016 40
Huntington Disease - Pipeline by BioMarin Pharmaceutical Inc., H1 2016 41
Huntington Disease - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2016 42
Huntington Disease - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016 43
Huntington Disease - Pipeline by EncephRx, Inc., H1 2016 44
Huntington Disease - Pipeline by Evotec AG, H1 2016 45
Huntington Disease - Pipeline by Galenea Corp., H1 2016 46
Huntington Disease - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016 47
Huntington Disease - Pipeline by Immungenetics AG, H1 2016 48
Huntington Disease - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 49
Huntington Disease - Pipeline by Ipsen S.A., H1 2016 50
Huntington Disease - Pipeline by Kadmon Corporation, LLC, H1 2016 51
Huntington Disease - Pipeline by KineMed, Inc., H1 2016 52
Huntington Disease - Pipeline by Living Cell Technologies Limited, H1 2016 53
Huntington Disease - Pipeline by Medesis Pharma S.A., H1 2016 54
Huntington Disease - Pipeline by Mitochon Pharmaceuticals, Inc., H1 2016 55
Huntington Disease - Pipeline by Neuralstem, Inc., H1 2016 56
Huntington Disease - Pipeline by Neurimmune Holding AG, H1 2016 57
Huntington Disease - Pipeline by NeuroNascent, Inc., H1 2016 58
Huntington Disease - Pipeline by New World Laboratories, Inc., H1 2016 59
Huntington Disease - Pipeline by nLife Therapeutics, S.L., H1 2016 60
Huntington Disease - Pipeline by NsGene A/S, H1 2016 61
Huntington Disease - Pipeline by Omeros Corporation, H1 2016 62
Huntington Disease - Pipeline by Oryzon Genomics S.A., H1 2016 63
Huntington Disease - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 64
Huntington Disease - Pipeline by Pfizer Inc., H1 2016 65
Huntington Disease - Pipeline by PharmatrophiX, Inc., H1 2016 66
Huntington Disease - Pipeline by ProQR Therapeutics N.V., H1 2016 67
Huntington Disease - Pipeline by QR Pharma, Inc., H1 2016 68
Huntington Disease - Pipeline by Raptor Pharmaceutical Corp., H1 2016 69
Huntington Disease - Pipeline by reMYND NV, H1 2016 70
Huntington Disease - Pipeline by Rhenovia Pharma Limited, H1 2016 71
Huntington Disease - Pipeline by Sangamo BioSciences, Inc., H1 2016 72
Huntington Disease - Pipeline by SOM Innovation Biotech SL, H1 2016 73
Huntington Disease - Pipeline by Spark Therapeutics, Inc., H1 2016 74
Huntington Disease - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 75
Huntington Disease - Pipeline by TyrNovo Ltd., H1 2016 76
Huntington Disease - Pipeline by Ultragenyx Pharmaceutical Inc., H1 2016 77
Huntington Disease - Pipeline by UniQure N.V., H1 2016 78
Huntington Disease - Pipeline by Vaccinex, Inc., H1 2016 79
Huntington Disease - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 80
Huntington Disease - Pipeline by VistaGen Therapeutics , Inc., H1 2016 81
Huntington Disease - Pipeline by VivaCell Biotechnology Espana S.L., H1 2016 82
Huntington Disease - Pipeline by Voyager Therapeutics, Inc., H1 2016 83
Huntington Disease - Pipeline by Vybion, Inc., H1 2016 84
Huntington Disease - Pipeline by WAVE Life Sciences Ltd., H1 2016 85
Huntington Disease - Pipeline by Wellstat Therapeutics Corporation, H1 2016 86
Assessment by Monotherapy Products, H1 2016 87
Number of Products by Stage and Target, H1 2016 89
Number of Products by Stage and Mechanism of Action, H1 2016 92
Number of Products by Stage and Route of Administration, H1 2016 95
Number of Products by Stage and Molecule Type, H1 2016 97
Huntington Disease Therapeutics - Recent Pipeline Updates, H1 2016 230
Huntington Disease - Dormant Projects, H1 2016 288
Huntington Disease - Dormant Projects (Contd..1), H1 2016 289
Huntington Disease - Dormant Projects (Contd..2), H1 2016 290
Huntington Disease - Dormant Projects (Contd..3), H1 2016 291
Huntington Disease - Dormant Projects (Contd..4), H1 2016 292
Huntington Disease - Dormant Projects (Contd..5), H1 2016 293
Huntington Disease - Dormant Projects (Contd..6), H1 2016 294
Huntington Disease - Discontinued Products, H1 2016 295

List of Figures
Number of Products under Development for Huntington Disease, H1 2016 19
Number of Products under Development for Huntington Disease - Comparative Analysis, H1 2016 20
Number of Products under Development by Companies, H1 2016 21
Number of Products under Investigation by Universities/Institutes, H1 2016 25
Comparative Analysis by Late Stage Development, H1 2016 27
Comparative Analysis by Clinical Stage Development, H1 2016 28
Comparative Analysis by Early Stage Products, H1 2016 29
Assessment by Monotherapy Products, H1 2016 87
Number of Products by Top 10 Targets, H1 2016 88
Number of Products by Stage and Top 10 Targets, H1 2016 88
Number of Products by Top 10 Mechanism of Actions, H1 2016 91
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 91
Number of Products by Top 10 Routes of Administration, H1 2016 94
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 94
Number of Products by Top 10 Molecule Types, H1 2016 96
Number of Products by Stage and Top 10 Molecule Types, H1 2016 96

Summary of Source & Methodology

True

Global Markets Direct follows the highest standards when conducting primary and secondary research, including thousands of interviews with senior executives every year, to enable clients to make sound business decisions for their company in complete confidence. 1. 1 million-strong stakeholder group, plus 25,000 interviews annually 2. Rigorous checks on over 25,000 public and proprietary sources 3. Data modeled and forecasted with gold-standard methodology 4. Updated in real time 5. Expert insights and critical analysis from 700 experienced researchers and analysts If you would like to request the complete research methodology of this report or any additional information, please send us an email to reports@zursh.com

Download additional documents & original sources used by researcher/publisher to support the report data

Download Documents
No documents available for download

Zursh quality control analysts have developed a nice rating algorithm to independently and objectively evaluate the quality of this report.

Quality Score : 5
Content 5
Reputation 5
Sources 5
Presentation 5
Global Markets Direct is a leading provider of global business intelligence and market analysis. The company publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. At the heart of Global Markets Direct are unique databases, updated live, covering millions of rows of key information for the studied industry at a global level.